Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
March 18th, 2008
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, reported publication of a new preclinical study in Clinical Cancer Research that supports the specific tumor targeting properties of the company's novel anti-phosphatidylserine (anti-PS) antibody platform. Peregrine's most advanced anti-PS monoclonal antibody, bavituximab, is currently in Phase II cancer trials in combination with chemotherapy. The newly published study demonstrates that in a model of prostate cancer, bavituximab's phosphatidylserine target is specifically exposed in...
Source: Cancer Weekly (2008-03-18)
|
